AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology
Shots:
- AbbVie and EvolveImmune Therapeutics have entered into a partnership & option-to-license agreement for the development of multispecific biologics targeting various cancer pathways
- As per the agreement, EvolveImmune is entitled to receive $65M upfront & equity investment plus $1.4B option payment & milestones along with net-sales based tiered royalties
- The collaboration will employ AbbVie's knowledge in oncology and EvolveImmune's EVOLVE T-Cell Engager Platform for solid & hematologic malignancies. The platform is designed to enhance T-cell activation to improve their tumor killing ability & reduce T-cell dysfunction
Ref: AbbVie | Image: AbbVie & EvolveImmune
Related News:- AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
